New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Syn-Ake

Pancragen vs Syn-Ake

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Skin & CosmeticAnti-Aging & Longevity
Syn-Ake
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
Half-Life
Short (minutes); sustained gene-regulatory effects
Not applicable (topical; effect duration hours)
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
0.01–0.1% (4–8 mg/g in clinical studies)
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Reduces depth of dynamic wrinkles and expression lines
  • Reversible muscle-relaxing effect on facial muscles
  • Smooths forehead lines, crow's feet, and frown lines
  • Non-invasive alternative to injectable neurotoxins
  • Rapid onset relative to collagen-stimulating peptides
  • Well-studied in in vitro and clinical cosmetic trials
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally very well-tolerated topically
  • Rare skin sensitivity or contact dermatitis
  • Theoretical neuromuscular effects at systemic doses (not relevant topically)
Stacks With